Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 27Terminated 8Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 10Gynecologic 5Genitourinary 4Endocrine 4NET 3Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2Head & Neck 2Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Rituximab 129Cyclophosphamide 122Doxorubicin 62Vincristine 61venetoclax 58Prednisone 57ibrutinib 52Specimen Handling 50fludarabine 47Lenalidomide 47Biopsy 46obinutuzumab 43acalabrutinib 42Etoposide 41fludarabine phosphate 36Magnetic Resonance Spectroscopy 36Cytarabine 35CT-P10 35Dexamethasone 34Methotrexate 29Bendamustine Hydrochloride 27pembrolizumab 26Nivolumab 22blinatumomab 21zanubrutinib 20prednylidene 19Calcium Dobesilate 19deltacortene 18Radiotherapy 18Melphalan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Everolimus × Lymphoid × Clear all
NCT03740334 2025-11-21

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
45 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡